For research use only. Not for therapeutic Use.
VIP152, also known as BAY 1251152, is a Highly Potent and Selective CDK9 Inhibitor, which is Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. VIP152 exhibited the best preclinical overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats upon once weekly iv administration. VIP152 has entered clinical trials for the treatment of cancer with promising longterm, durable monotherapy activity in double-hit diffuse large B-cell lymphoma patients.
| Catalog Number | I038070 |
| CAS Number | 1610408-97-3 |
| Synonyms | VIP152; VIP-152; VIP 152; BAY 1251152; BAY1251152; BAY-1251152; |
| Molecular Formula | C19H18F2N4O2S |
| Purity | 98% |
| Solubility | To be determined |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (S)-((2-((5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyridin-2-yl)amino)pyridin-4-yl)methyl)(imino)(methyl)-l6-sulfanone |
| InChI | InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)/t28-/m0/s1 |
| InChIKey | YZCUMZWULWOUMD-NDEPHWFRSA-N |
| SMILES | FC(C=N1)=C(C2=C(OC)C=C(F)C=C2)C=C1NC3=CC(C[S@](C)(=O)=N)=CC=N3 |
| Reference | 1: Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. J Med Chem. 2021 Jul 15. doi: 10.1021/acs.jmedchem.1c01000. Epub ahead of print. PMID: 34264057. |
